Meeting
2022 ASCO Annual Meeting
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
Authors
Lingying Wu
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Lingying Wu , Jing Wang , Li Wang , Weiguo Lu , Ke Wang , An Lin , Ning Li , Li Li , Ning Su , Shuang Xie , Jun Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5567)
DOI
10.1200/JCO.2022.40.16_suppl.5567
Abstract #
5567
Poster Bd #
445
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
First Author: Leslie M. Randall
Poster
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
First Author: Haider Mahdi
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2022 ASCO Annual Meeting
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
First Author: Ursula A. Matulonis